Ownership and insider activity for Absci Corporation (ABSI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States.
Price
| Price | $8.04 |
| Market Cap | $1.4B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-31 | Jonasson Zachariah | F-InKind | 8,320 | $72K |
| 2026-03-03 | Somaratne Ransi Mudalinayake | A-Award | 650,000 | $1.7M |
| 2026-08-03 | Somaratne Ransi Mudalinayake | A-Award | 383,000 | $3.0M |
| 2026-03-03 | Somaratne Ransi Mudalinayake | |||
| 2026-06-30 | Szela Mary T | P-Purchase | 12,900 | $149K |
| 2026-06-24 | McClain Sean | F-InKind | 59,896 | $603K |
| 2026-06-04 | Szela Mary T | A-Award | 33,200 | $244K |
| 2026-06-04 | Szela Mary T | A-Award | 8,400 | |
| 2026-06-04 | MCGINNIS KAREN K | A-Award | 10,100 | |
| 2026-06-04 | MCGINNIS KAREN K | A-Award | 39,800 | $292K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.1M | $69.9M | $252.6M | $60.0M | $72.4M | $41.2M | $20.0M |
| Short-term Investments | 0 | 0 | 0 | $104.5M | $25.3M | $71.2M | $124.3M |
| Receivables | $222000 | $1.6M | $1.4M | $1.6M | $2.2M | 0 | 0 |
| Inventory | 0 | 0 | $10.5M | $15.0M | 0 | 0 | 0 |
| Total Current Assets | $13.6M | $73.2M | $273.1M | $186.9M | $120.6M | $133.8M | $149.6M |
| Property, Plant & Equipment | $5.0M | $13.4M | $58.7M | $58.0M | $45.8M | $33.1M | $23.8M |
| Goodwill | 0 | 0 | $21.3M | $21.3M | 0 | 0 | 0 |
| Intangible Assets | $283000 | 0 | $55.0M | $51.6M | $48.3M | $44.9M | $41.5M |
| Total Assets | $19.5M | $88.6M | $426.2M | $321.0M | $217.3M | $213.6M | $216.3M |
| Accounts Payable | $268000 | $2.1M | $8.4M | $2.4M | $1.5M | $3.5M | $2.8M |
| Short-term Debt | $1.2M | $1.5M | $2.4M | $2.9M | $3.3M | $2.7M | $873000 |
| Total Current Liabilities | $3.5M | $10.1M | $33.9M | $30.3M | $29.6M | $28.7M | $22.8M |
| Long-term Debt | $1.7M | $4.1M | $1.1M | $8.0M | $4.7M | $1.3M | 0 |
| Total Liabilities | $60.6M | $21.6M | $60.1M | $46.6M | $41.1M | $34.5M | $26.8M |
| Retained Earnings | -$41.4M | -$90.1M | -$191.0M | -$295.9M | -$406.5M | -$509.6M | -$624.8M |
| Total Equity | -$41.2M | $67.0M | $366.1M | $274.4M | $176.2M | $179.1M | $189.4M |
| Total Debt | $6.0M | $14.5M | $20.0M | $23.0M | $15.9M | $10.1M | $5.3M |
| Net Debt | -$7.1M | -$55.4M | -$232.6M | -$141.4M | -$81.8M | -$102.3M | -$139.0M |
| Working Capital | $10.2M | $63.1M | $239.2M | $156.6M | $91.0M | $105.2M | $126.8M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 10.63 |
Profitability
| Return on Equity | -59.21% |
| Return on Invested Capital | -52.24% |
| Return on Assets | -45.02% |
| Gross Margin | -255.93% |
| Operating Margin | -8411.27% |
| Net Margin | -7756.37% |
Related companies: CRVS · ERAS · GOSS · MGTX · MLTX · OLMA · PRTA
Explore sector: Healthcare · Biotechnology
More sections of ABSI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks